- Screening
- Preoperative indications
- Intraoperative indications
- Follow-up one week after aspiration
- Adverse events
- Follow-up 2
- Follow-up 3
- Management system of participants
- Speciman management system
- Data management system
- ADR/ADE management system
- Madicine management system
- Instruments management system
- SOPs
- Research team
- Design, Methods
Informed consent | Yes
|
nodule with high insufficient rate | suspected degenerative nodule
|
US assessment accords with FNA criteria recommended by C-TIRADS | Yes
/No
|
Thyroid US indicates thyroid nodule. | Yes
|
Age ≥ 18 years old | Yes
|
Patients unable to cooperate for FNA or CEUS | No
|
Active infectious focus on cervical skin | No
|
Pregnancy | No
|
Severe abnormality of coagulation function | No
|
Severe abnormality of heart function or lung function | No
|
Refuse to CEUS | No
|
Allergic to lidocaine or SonoVue | No
|
Birthday | 1983-05-02 |
Registration number | 1000047745 |
Date for signing informed consent | 2023-06-06 |
Telephone | 13570421523 |
Sex | Female
|
Rank of ACR TI-RADS | 5 |
Score of ACR TI-RADS | 10 |
Solid component of sheet-like strong echo (%) | - |
Strong echo within nodule | No
|
acoustic halo | No
|
border | angled
|
edge | unclear
|
echo | extremely hypoecho
|
Solid component (%) | 100 |
Upper and lower diameter | 8 mm |
Anteroposterior diameter | 12 mm |
Coagulation function | Yes
|
transverse diameter | 9 mm |
Routine blood test | Yes
|
Location of target thyroid nodule | right lobe
|
VCs function evaluated by TLUSG | bilateral VCs moved symmetrically
|
Ultrasonic diagnose | 退变结节与肿瘤鉴别 |
Rank of C-TIRADS | 4c |
Score of C-TIRADS | 4 |
- Time of aspiration
- Contrast-enhance indication (CEUS-FNA group)
- Progression of operation
- Intraoperative instant complication
End time | 16:24 |
Start time | 16:13 |
Date of aspiration | 2023-06-06 |
Injection of SonoVue during FNA | No
|
Ratio of enhancement | 50 |
No enhancement | No
|
Dosage of SonoVue | 2 |
other local anaesthesics | - |
Local anesthesia | 2% lidocaine
|
Machine | GE logiq E9
|
Sample capacity | medium
|
Grittiness | Suspected
|
Quality of nodule | solid
|
Pressure | - ml |
Use of negative pressure | No
|
Aspiration times | 4 |
FNA approach | lateral approach
|
Aspiration needle | Italy 23G
|
Patient compliance | good
|
Dosage of local anaesthesics | 4 ml |
methods | |
Haemorrhage | No
|
extend of hematoma (once after FNA) |
|
Painful when leave interventional room | No
|
visible for bleeding by CDFI | |
Analgesic | No
|
location | |
VAS score | 2 |
Painful | Yes
|
Allergic to contrast agent | No
|
whether the voice recovers when the patient leaves | |
methods | |
vocal cord mobility assessment by ultrasound | |
Aspiration related acute hypersensitivity reaction | No
|
appearance | |
Horner syndrome | No
|
extend of hematoma (before patient departure) | |
Vagal nerve syndrome | No
|
visible hemorrhage by CDFI 30 minutes after FNA | |
Voice change | No
|
Cytopathology classification | |
Number of observable follicular epithelial cell clusters in specimen | |
Whether sample capacity is enough | |
Pathological number |
|